Leriglitazone hydrochloride Hydroxypioglitazone hydrochloride,99.0%
产品编号:Bellancom-117727A| CAS NO:146062-46-6| 分子式:C19H21ClN2O4S| 分子量:408.90
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
Leriglitazone hydrochloride Hydroxypioglitazone hydrochloride
产品介绍 | Leriglitazone (Hydroxypioglitazone) hydrochloride,吡格列酮的代谢产物。Leriglitazone (Hydroxypioglitazone) hydrochloride是 PPARγ 激动剂,通过稳定 PPARγ (AF-2) 共激活剂结合表面和增强共激活剂结合能力,提供高转录效力。 Leriglitazone (Hydroxypioglitazone) hydrochloride 与 PPARγC (LBD) 结合,其 Ki 值为 1.2 μM,诱导 PPARγ (LBD) 转录效率,EC50 为 680 nM。 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | Leriglitazone (Hydroxypioglitazone) hydrochloride, a metabolite of pioglitazone. Leriglitazone (Hydroxypioglitazone) hydrochloride PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy. Leriglitazone (Hydroxypioglitazone) hydrochloride binds to the PPARγ C-terminal ligand-binding domain (LBD) with a Ki of 1.2 μM,Leriglitazone induces transcriptional efficacy of the PPARγ (LBD) with an EC50 of 680 nM. | ||||||||||||||||
体外研究 | |||||||||||||||||
体内研究 | |||||||||||||||||
体内研究 | |||||||||||||||||
性状 | Solid | ||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 50 mg/mL (122.28 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | ||||||||||||||||
参考文献 |